Cell therapy operations and manufacturing fact sheet

The complexity of delivering autologous CAR T cell therapies is unlike any other traditional biologic or small molecule medicine, using a patient’s own cells to start a highly sophisticated and personalized manufacturing process. Bristol Myers Squibb is advancing the field of cell therapy through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highly trained manufacturing teams.

Cell therapy manufacturing footprint and network

Each day, BMS employees around the world work together for patients, who are at the center of everything we do. We continue making significant investments to expand and optimize our global manufacturing network to bring cell therapy treatments to more patients in need.